What changed
Corrected the cited clinical review from 2007 to 1999 and separated NDA 19-863 for the diagnostic formulation from NDA 20-443 for the treatment product.
Source record · FDA approval and discontinued-product record · reviewed July 17, 2026
Historical Geref approval is not a current anti-aging approval.
The circulating claim“Sermorelin is an FDA-approved anti-aging peptide.”
What the source record says
FDA records document historical Geref products under NDA 19-863 for a diagnostic formulation and NDA 20-443 for a treatment product. Both remain on the discontinued-product list. FDA said they were not withdrawn for safety or effectiveness reasons, but that does not create an anti-aging indication or prove a current product is equivalent to Geref.
Why the claim misleads
Historical approval, reason for discontinuation, current product identity, and a new wellness indication are four separate questions.
Correction
Historical Geref approval is not a current anti-aging approval.
Primary sources
FDA Geref diagnostic approval package, NDA 19-863Open source ↗FDA Federal Register notice, 2013Open source ↗Sermorelin library entryOpen source ↗What would change our answer
A current FDA approval or well-controlled adult trial tied to a defined product and outcome could change the answer. Historical discontinuation language alone cannot.
Version history · 2 entries
Boundary: This check evaluates a public claim. It does not assess an individual product or person and is not treatment, dosing, sourcing, or legal advice.